SNAP
BIG 2-12
Schedules of Nab-Paclitaxel: evaluation of different schedules of nab-paclitaxel for metastatic breast cancer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Contenu de va-et-vient
Contenu de va-et-vient
This trial is coordinated and sponsored by the International Breast Cancer Study Group (IBCSG) under the umbrella of the Breast International Group.
Pharmaceutical partner: Celgene
Contenu de va-et-vient
Contenu de va-et-vient
Contenu de va-et-vient
Funding: Celgene grant
More To Explore
DECRESCENDO
DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share